Orbifloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Orbifloxacin
DrugBank Accession Number
DB11443
Background

Orbifloxacin is a fluoroquinolone antibiotic. It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 395.382
Monoisotopic: 395.145676005
Chemical Formula
C19H20F3N3O3
Synonyms
  • Orbifloxacin

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Orbifloxacin.
AceclofenacAceclofenac may increase the neuroexcitatory activities of Orbifloxacin.
AcemetacinAcemetacin may increase the neuroexcitatory activities of Orbifloxacin.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Orbifloxacin.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Orbifloxacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Orbax

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Aryl fluorides / Benzenoids
show 13 more
Substituents
1,4-diazinane / Amine / Amino acid / Amino acid or derivatives / Aminoquinoline / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
660932TPY6
CAS number
113617-63-3
InChI Key
QIPQASLPWJVQMH-DTORHVGOSA-N
InChI
InChI=1S/C19H20F3N3O3/c1-8-5-24(6-9(2)23-8)17-14(21)13(20)12-16(15(17)22)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6H2,1-2H3,(H,27,28)/t8-,9+
IUPAC Name
1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
[H][C@]1(C)CN(C[C@@]([H])(C)N1)C1=C(F)C(F)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O

References

General References
  1. Harada K, Shimizu T, Kataoka Y, Takahashi T: Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs. Acta Vet Scand. 2012 Mar 20;54:16. doi: 10.1186/1751-0147-54-16. [Article]
  2. Haines GR, Brown MP, Gronwall RR, Merritt KA, Baltzley LK: Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. Can J Vet Res. 2001 Jul;65(3):181-7. [Article]
  3. Llorent-Martinez EJ, Ortega-Barrales P, Molina-Diaz A, Ruiz-Medina A: Implementation of terbium-sensitized luminescence in sequential-injection analysis for automatic analysis of orbifloxacin. Anal Bioanal Chem. 2008 Dec;392(7-8):1397-403. doi: 10.1007/s00216-008-2434-9. Epub 2008 Oct 29. [Article]
  4. Morimura T, Nobuhara Y, Matsukura H: Photodegradation products of a new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution. Chem Pharm Bull (Tokyo). 1997 Feb;45(2):373-7. [Article]
  5. Morimura T, Ohno T, Matsukura H, Nobuhara Y: Photodegradation kinetics of the new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution. Chem Pharm Bull (Tokyo). 1995 Jun;43(6):1000-4. [Article]
  6. Szczypka M, Gaweda B, Obminska-Mrukowicz B: Modulation of cellular immune response by orbifloxacin in noninfected and E. coli-infected mice. Immunopharmacol Immunotoxicol. 2005;27(3):461-72. [Article]
  7. Davis JL, Papich MG, Weingarten A: The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. J Vet Pharmacol Ther. 2006 Jun;29(3):191-7. [Article]
  8. Gebru E, Lee SJ, Kim JC, Park SC: Allometric scaling of orbifloxacin disposition in nine mammal species: a retrospective analysis. J Vet Med Sci. 2011 Jun;73(6):817-20. Epub 2011 Jan 12. [Article]
  9. Hawkins MG, Taylor IT, Byrne BA, Armstrong RD, Tell LA: Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail (Coturnix japonica) following oral and intravenous administration. J Vet Pharmacol Ther. 2011 Aug;34(4):350-8. doi: 10.1111/j.1365-2885.2010.01233.x. Epub 2010 Oct 11. [Article]
KEGG Drug
D08299
ChemSpider
54631
RxNav
995897
ChEMBL
CHEMBL295433
ZINC
ZINC000003882891
Wikipedia
Orbifloxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0254 mg/mLALOGPS
logP0.36ALOGPS
logP0.25Chemaxon
logS-4.2ALOGPS
pKa (Strongest Acidic)5.49Chemaxon
pKa (Strongest Basic)8.77Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area72.88 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity97.21 m3·mol-1Chemaxon
Polarizability37.69 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0009000000-5cad3fcb302dbc5998d6
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000x-0009000000-ecaa4989a4a6c373b8dd
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-0009000000-42b9cdf9480f4afc616f
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0f6x-0109000000-8bb9bee8e09b6bb2fb39
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00bj-0009000000-cbd50dbb45b75abe0543
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-052r-0009000000-2cc312877714db2ca58e
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-188.86269
predicted
DeepCCS 1.0 (2019)
[M+H]+191.25822
predicted
DeepCCS 1.0 (2019)
[M+Na]+197.17076
predicted
DeepCCS 1.0 (2019)

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
Curator comments
This drug is a quinolone derivative, and these agents are known to inhibit CYP1A2.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Shahzadi A, Javed I, Aslam B, Muhammad F, Asi MR, Ashraf MY, Zia-ur-Rahman: Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci. 2011 Jan;24(1):63-8. [Article]
  2. Fuhr U, Strobl G, Manaut F, Anders EM, Sorgel F, Lopez-de-Brinas E, Chu DT, Pernet AG, Mahr G, Sanz F, et al.: Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol. 1993 Feb;43(2):191-9. [Article]
  3. Get to Know an Enzyme: CYP1A2 [Link]

Drug created at February 25, 2016 18:49 / Updated at February 21, 2021 18:53